EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Nation-wide cohort study of remission induction therapy using rituximab in Japanese patients with antineutrophil cytoplasmic antibody–associated vasculitis: Effectiveness and safety in the first 6 months

Kenji Nagasaka, Koichi Amano, Hiroaki Dobashi, Hiroko Nagafuchi, Ken-Ei Sada, Yoshinori Komagata, Masahiro Yamamura, Masaru Kato, Tomomi Endo, Izaya Nakaya, Tsutomu Takeuchi, Yohko Murakawa und 12 weitere

Modern Rheumatology · 2024

DOI: 10.1093/mr/roac150 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Kenji Nagasaka und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan. Hauptthemen laut MEDLINE: Granulomatosis with Polyangiitis, Microscopic Polyangiitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health, Labour and Welfare, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The aim of this article is to evaluate the effectiveness and safety of rituximab (RTX) for microscopic polyangiitis and granulomatosis with polyangiitis in Japan.

Methods

In this prospective observational study, all patients with microscopic polyangiitis and granulomatosis with polyangiitis administered RTX were enrolled at each institution. During the observation period of 2 years, data up to 6 months were analysed. Cox proportional hazards analysis was used to assess the factors associated with an outcome.

Results

Of the 75 patients who received RTX for remission induction therapy, 53 achieved remission by the sixth month and 50 were in remission at the sixth month. During therapy, 39 serious adverse events were observed in 24 patients, 21 serious infections in 16 patients, and 9 patients died. No factors were associated with remission; however, there was a significant difference between patients with and without remission in serious adverse events (22.6% vs. 54.5%), serious infections (11.3% vs. 45.4%), and death (1.9% vs. 36.4%). The hazard ratio (95% confidence interval) for serious infection was 3.49 (1.29–9.74) for patients aged ≥ 75 years and 3.53 (1.31–9.53) for pulmonary complications. Four patients maintained remission for 6 months.

Conclusions

The effectiveness and safety of RTX for microscopic polyangiitis and granulomatosis with polyangiitis for up to 6 months was demonstrated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulomatosis with PolyangiitisMicroscopic PolyangiitisAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisHumansRituximabAntibodies, Antineutrophil CytoplasmicCohort StudiesEast Asian PeopleTreatment OutcomeRemission Induction

Stichwörter der Autor:innen

ANCA-associated vasculitisremissionrituximabserious infection

Substanzen

RituximabAntibodies, Antineutrophil Cytoplasmic

Autor:innen und Institutionen

  • Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan.
  • Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
  • Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Division of Rheumatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
  • Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

ORCID-Profile: Masayoshi Harigai

Förderung

  • Ministry of Health, Labour and Welfare
  • Japan Agency for Medical Research and Development

Zitieren

APA

Nagasaka, K., Amano, K., Dobashi, H., Nagafuchi, H., Sada, K. E., Komagata, Y., Yamamura, M., Kato, M., Endo, T., Nakaya, I., Takeuchi, T., Murakawa, Y., Sugihara, T., Saito, M., Hayashi, T., Furuta, S., Tamura, N., Karasawa, K., Banno, S., …, & Harigai, M. (2024). Nation-wide cohort study of remission induction therapy using rituximab in Japanese patients with antineutrophil cytoplasmic antibody–associated vasculitis: Effectiveness and safety in the first 6 months. Modern Rheumatology. https://doi.org/10.1093/mr/roac150

Vancouver

Nagasaka K, Amano K, Dobashi H, Nagafuchi H, Sada KE, Komagata Y, et al. Nation-wide cohort study of remission induction therapy using rituximab in Japanese patients with antineutrophil cytoplasmic antibody–associated vasculitis: Effectiveness and safety in the first 6 months. Modern Rheumatology. 2024. doi:10.1093/mr/roac150

BibTeX
@article{Nagasaka2024,
  author = {Nagasaka, Kenji and Amano, Koichi and Dobashi, Hiroaki and Nagafuchi, Hiroko and Sada, Ken-Ei and Komagata, Yoshinori and Yamamura, Masahiro and Kato, Masaru and Endo, Tomomi and Nakaya, Izaya and Takeuchi, Tsutomu and Murakawa, Yohko and Sugihara, Takahiko and Saito, Masaya and Hayashi, Taichi and Furuta, Shunsuke and Tamura, Naoto and Karasawa, Kazunori and Banno, Shogo and Endo, Shuichiro and Majima, Masako and Kaname, Shinya and Arimura, Yoshiriro and Harigai, Masayoshi},
  title = {Nation-wide cohort study of remission induction therapy using rituximab in Japanese patients with antineutrophil cytoplasmic antibody–associated vasculitis: Effectiveness and safety in the first 6 months},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/roac150}
}
Kostenlos starten →